NCT06202196 Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy
| NCT ID | NCT06202196 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 74 participants |
| Start Date | 2024-04-16 |
| Primary Completion | 2028-04-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 74 participants in total. It began in 2024-04-16 with a primary completion date of 2028-04-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pilot, controled, randomized study aiming to evaluate a plan for the prevention of risks related to epilepsy, 3 months after the last therapeutic patient education session. Two groups of patients will be compared: group "intervention" (consultation with the neurologist then a psychologist followed by a session dedicated to risk prevention ("Recognize and Manage risks") integrated into usual Therapeutic Patient Education (TPE) versus "control" group (usual consultations with the neurologist and usual TPE). 37 subjects per group will be included in this study.
Eligibility Criteria
Inclusion Criteria: * Patient between 18 and 60 years old * Patient with poorly controlled epilepsy (persistence of seizures evolving for more than a year despite proper treatment) or patient seizure-free for over a year but for whom therapeutic patient education (TPE) would be beneficial according to the investigator.. * Patient agreeing to participate in a therapeutic education program (TPE) Exclusion Criteria: * Epileptic patient who has already benefited from a TPE epilepsy program * Patients with major cognitive impairment * Patient under guardianship or legal protection (safeguard of justice) * Pregnant or breast-feeding women * Failure to obtain written informed consent after a reflection period * Patient who for geographical, social or psychological reasons could not participate in the research * Any situation that, in the opinion of the investigator, could present risks to the patient and to the research * Participation in another therapeutic research * Subjects not covered by public health insurance
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06202196 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06202196 currently recruiting?
Yes, NCT06202196 is actively recruiting participants. Contact the research team at a-catheland@chu-montpellier.Fr for enrollment information.
Where is the NCT06202196 trial being conducted?
This trial is being conducted at Montpellier, France, Toulouse, France.
Who is sponsoring the NCT06202196 clinical trial?
NCT06202196 is sponsored by University Hospital, Montpellier. The trial plans to enroll 74 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.